WO1997003054A1 - BENZO[g]QUINOLINE DERIVATIVES - Google Patents

BENZO[g]QUINOLINE DERIVATIVES Download PDF

Info

Publication number
WO1997003054A1
WO1997003054A1 PCT/EP1996/002969 EP9602969W WO9703054A1 WO 1997003054 A1 WO1997003054 A1 WO 1997003054A1 EP 9602969 W EP9602969 W EP 9602969W WO 9703054 A1 WO9703054 A1 WO 9703054A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
acid addition
free base
salt form
Prior art date
Application number
PCT/EP1996/002969
Other languages
French (fr)
Inventor
Peter Neumann
Paul Pfaeffli
Max Peter Seiler
Robert Swoboda
Original Assignee
Novartis Ag
Novartis-Erfindungen Verwaltungsgesellschaft Mbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9513880.6A external-priority patent/GB9513880D0/en
Priority claimed from GBGB9603988.8A external-priority patent/GB9603988D0/en
Priority to NZ313606A priority Critical patent/NZ313606A/en
Priority to EP96925672A priority patent/EP0839136B1/en
Priority to DE69612852T priority patent/DE69612852T2/en
Priority to BR9609326A priority patent/BR9609326A/en
Priority to US08/983,535 priority patent/US5885988A/en
Priority to DK96925672T priority patent/DK0839136T3/en
Priority to PL96324106A priority patent/PL324106A1/en
Priority to AU66120/96A priority patent/AU703325B2/en
Application filed by Novartis Ag, Novartis-Erfindungen Verwaltungsgesellschaft Mbh filed Critical Novartis Ag
Priority to JP9505489A priority patent/JPH11509197A/en
Priority to IL12285496A priority patent/IL122854A/en
Priority to AT96925672T priority patent/ATE201199T1/en
Priority to SI9630315T priority patent/SI0839136T1/en
Priority to SK17-98A priority patent/SK1798A3/en
Publication of WO1997003054A1 publication Critical patent/WO1997003054A1/en
Priority to MXPA/A/1997/010530A priority patent/MXPA97010530A/en
Priority to NO980043A priority patent/NO310070B1/en
Priority to GR20010401198T priority patent/GR3036346T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/08—Aza-anthracenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems

Definitions

  • the present invention relates to novel benzo[g]quinoline derivatives, their preparation, their use as pharmaceuticals and pharmaceutical compositions comprising them.
  • X O or H,H
  • Y is -CH 2 -,.-O-, -NH- or -S-,
  • R is H or (C M )alkyl
  • R 2 is H, benzyl, pyrimidyl, bis(4-fluorophenyl)methyl or a group of formula
  • R 5 is H or (C )alkyl and Rg, R 7 , R 8 and Rg independently are H, OH, NO 2 , CF 3 , (C M )alkyl, acetyl, CONR 10 R n , COOR 12 [R ⁇ and R 12 independently being H or (C M )alkyl], CN or (C M )alkylsulfonyl, R 3 is H, (C. alkyl, (C M )alkylsu.fonyl, trifluoromethylsulfonyl or a group of formula
  • n is 1 to 5 and m is 1 to 3, and R 4 is hydrogen or halogen, in free base or acid addition salt form.
  • the invention includes the enantiomers as well as their mixtures, e.g. the epimeric or racemic mixtures which may be present on account of the asymmetrical carbon atoms in positions 3, 4a and 10a.
  • the configuration [3R,4aR,10aR] is preferred.
  • Halogen is fluorine, chlorine, bromine or iodine, preferably chlorine or bromine.
  • the above-defined alkyl groups preferably represent methyl.
  • R 2 is H, benzyl, pyrimidyl, bis(4-fluorophenyl)methyl, naphthyl or a group of formula (a) as defined above or (b") or ( ⁇ -')
  • R' 6 and R' 7 independently are H, OH, NO 2 , CF 3 , acetyl, COOR 12 (R 12 being as defined above) or CN and R' g is H, NO 2 or CN; R 3 is in position 6 and is H, (C M )alkyl, methylsulfonyl, trifluoromethylsulfonyl or a group of formula
  • n and m are as defined above and R 4 is hydrogen, the configuration in positions 4a and 10a being R.
  • the invention provides a process for the production of the compounds of formula I and their acid addition salts, whereby a compound of formula 13
  • reaction can be effected according to known amide formation methods, for example as described in Example 1.
  • M as an alkali metal is for example sodium.
  • Acid addition salts may be produced from the free bases in known manner, and vice versa.
  • Suitable acid addition salts for use in accordance with the present invention include for example the hydrochloride.
  • the starting compounds of formula II may be produced from the corresponding compounds of formula IV
  • agents of the invention exhibit valuable pharmacological properties when tested in vitro using SRIF receptor expressing cell cultures and in animals, and are therefore useful as pharmaceuticals.
  • the agents of the invention bind to somatostatin receptors. More particularly they are selective antagonists at Somatostatin sst, receptors, previously called SSTR-1 receptors (see Hoyer et al., TiPS, 1995, 16; 86-88), as determined in radioligand binding and second messenger studies [see for example K. Kaupmann et al., FEBS LETTERS 1993, _3 ⁇ : 53-59] where they exhibit selective affinity for sstj receptors with pIC 50 values between about 7.5 and 9.5.
  • the agents of the invention are therefore useful for treatment in anxiety, depression, schizophrenia, neurodegenerative diseases such as dementia, for the treatment of tumors and for vascular disorders and immunological diseases, as confirmed in a range of standard tests as indicated below:
  • the agents of the invention increase exploratory behavior of mice in the open half of the half enclosed platform, a model which is predictable for anxiolytic activity (Psychopharmacology, 1986, 89:31-37).
  • the agents of the invention at the above indicated doses also increase vigilance of the mice.
  • the compounds are therefore indicated for the treatment of depression, schizophrenia and dementia, in particular of senile dementia of the Alzheimer type (SDAT).
  • the agents of the invention increase social investigation and reduce defensive ambivalence in the treated intruder mouse at indicated doses of about 1 to about 10 mg/kg s.c, suggesting an antidepressant profile like carbamazepine and lithium, a neuroleptic profile like clozapine and an anxiolytic profile like diazepam. Furthermore at said doses the compounds of the invention reduce aggressive behaviour (attacks, chases, bites) in the Matched Pairs Situation test in mice [Dixon et al., J. Clin. Psychiatry 55: (9) [Suppl.
  • the compounds of the invention exhibit an ethopharmacological profile which is very similar to that of carbamazepine, lithium chloride and clozapine. They are therefore indicated for the treatment of affective disorders including bipolar disorders e.g. manic-depressive psychoses, extreme psychotic states e.g. mania, schizophrenia, and excessive mood swings where behavioural stabilization is desired.
  • affective disorders including bipolar disorders e.g. manic-depressive psychoses, extreme psychotic states e.g. mania, schizophrenia, and excessive mood swings where behavioural stabilization is desired.
  • the compounds are indicated in anxiety states, generalized anxiety as well as social and agorophobia, as well as those behavioural states characterized by social withdrawal e.g. negative symptoms.
  • the agents of the invention are also effective in the treatment of various kinds of tumors, particularly of sst, receptor bearing tumors, as indicated in proliferation tests with various different cancer cell lines and in tumor growth experiments in nude mice with hormone dependent tumors [see for example: G. Weckbecker et al., Cancer Research 1994, _4: 6334- 6337].
  • the compounds are indicated in the treatment of, for example, cancers of the breast, the prostate, the colon, the pancreas, the brain and the lung (small cell lung cancer).
  • the appropriate dosage will of course vary depending upon, for example, the compound employed, the host, the mode of administration and the nature and severity of the condition being treated. However, in general, satisfactory results in animals are indicated to be obtained at a daily dosage of from about 0.1 to about 10 mg/kg animal body weight. In larger mammals, for example humans, an indicated daily dosage is in the range from about 5 to about 200 mg, preferably about 10 to about 100 mg of the compound conveniently administered in divided doses up to 4 times a day or in sustained release form.
  • the agents of the invention may be administered in free form or in pharmaceutically acceptable salt form.
  • Such salts may be prepared in conventional manner and exhibit the same order of activity as the free compounds.
  • the present invention provides selective sst, receptor antagonists for use as pharmaceuticals, more specifically for treatment in the above ⁇ mentioned conditions, e.g. depression, anxiety and bipolar disorders.
  • the present invention furthermore provides a pharmaceutical composition
  • a pharmaceutical composition comprising a selective sst, receptor antagonist, e.g. an agent of the invention in association with at least one pharmaceutically acceptable diluent or carrier.
  • Such compositions may be formulated in conventional manner.
  • Unit dosage forms contain, for example, from about 0.25 to about 50 mg of an agent according to the invention.
  • Selective sst, receptor antagonists, e.g. agents of the invention may be administered by any conventional route, for example parenterally e.g. in form of injectable solutions or sus ⁇ pensions, or enterally, preferably orally, e.g. in the form of tablets or capsules.
  • the preferred compound is [3R,4aR,10aR]-l,2,3,4,4a,5,10,10a- octahydro-6-methoxy- 1 -methyl-benzo[g]quinoline-3-carboxylic acid 4-(4-nitro-phenyl)- piperazine amide, which is the compound of example 1.
  • the preferred indications are depression, anxiety and affective disorders, including bipolar disorders, e.g. mania.
  • the present invention also provides the use of a selective sst, receptor antagonist, e.g. an agent of the invention, as a pharmaceutical, e.g. for the treatment of depression, anxiety and bipolar disorders.
  • a selective sst, receptor antagonist e.g. an agent of the invention
  • the present invention provides the use of a selective sst, receptor antagonist, e.g. an agent of the invention, for the manufacture of a medicament for the treatment of any condition mentioned above, e.g. depression, anxiety and affective disorders.
  • a selective sst, receptor antagonist e.g. an agent of the invention
  • the present invention provides a method for the treatment of any condition mentioned above, e.g. depression, anxiety and bipolar disorders, in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a selective sst, receptor antagonist, e.g. an agent of the invention.
  • a selective sst, receptor antagonist e.g. an agent of the invention.
  • Example 1 f3R. 4aR. 10aR1-1.2.3.4.4a.5.10.10a-octahvdro-6-methoxy-l-methyl- benzorglquinoline-3-carboxylic acid 4-( " 4-nitro-phenyl)-piperazine amide
  • X is O
  • Y is O
  • R is methyl
  • R 2 and R 3 are as indicated (OR 3 is in position 6) and R 4 is H.
  • X is H,H
  • Y is S
  • R is methyl
  • R 2 and R 3 are as indicated (OR 3 is in position 6) and R 4 is H.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention provides compounds of formula (I) wherein X, Y, R1, R2, R3 and R4 are as defined in the description, and a process for preparing them. The compounds of formula (I) are useful as pharmaceuticals.

Description

BENZOrglOUINOLINE DERIVATIVES
The present invention relates to novel benzo[g]quinoline derivatives, their preparation, their use as pharmaceuticals and pharmaceutical compositions comprising them.
More particularly the present invention provides a compound of formula I
Figure imgf000003_0001
wherein
X is = O or H,H
Y is -CH2-,.-O-, -NH- or -S-,
R, is H or (CM)alkyl,
R2 is H, benzyl, pyrimidyl, bis(4-fluorophenyl)methyl or a group of formula
Figure imgf000003_0002
(a) (b) (c) (d)
wherein R5 is H or (C )alkyl and Rg, R7, R8 and Rg independently are H, OH, NO2, CF3, (CM)alkyl, acetyl, CONR10Rn, COOR12 [Rπ and R12 independently being H or (CM)alkyl], CN or (CM)alkylsulfonyl, R3 is H, (C. alkyl, (CM)alkylsu.fonyl, trifluoromethylsulfonyl or a group of formula
Figure imgf000004_0001
wherein n is 1 to 5 and m is 1 to 3, and R4 is hydrogen or halogen, in free base or acid addition salt form.
The invention includes the enantiomers as well as their mixtures, e.g. the epimeric or racemic mixtures which may be present on account of the asymmetrical carbon atoms in positions 3, 4a and 10a. The configuration [3R,4aR,10aR] is preferred.
Halogen is fluorine, chlorine, bromine or iodine, preferably chlorine or bromine.
The above-defined alkyl groups preferably represent methyl.
In one group of compounds of formula I, X, Y and R, are as defined above, R2 is H, benzyl, pyrimidyl, bis(4-fluorophenyl)methyl, naphthyl or a group of formula (a) as defined above or (b") or (<-')
Figure imgf000004_0002
<W (< wherein R'6 and R'7 independently are H, OH, NO2, CF3, acetyl, COOR12 (R12 being as defined above) or CN and R'g is H, NO2 or CN; R3 is in position 6 and is H, (CM)alkyl, methylsulfonyl, trifluoromethylsulfonyl or a group of formula
Figure imgf000005_0001
wherein n and m are as defined above and R4 is hydrogen, the configuration in positions 4a and 10a being R.
In another group of compounds of formula I, X is = O, Y is -CH2- and R„ R2, R3 and R4 are as defined above.
In a further aspect the invention provides a process for the production of the compounds of formula I and their acid addition salts, whereby a compound of formula 13
Figure imgf000005_0002
wherein X, Y, R„ R3 and R4 are as defined above and M is H or an alkali metal, is reacted with a compound of formula HI
m
Figure imgf000005_0003
wherein R2 is as defined above, and the compounds of formula I thus obtained are recovered in free base or acid addition salt form.
The reaction can be effected according to known amide formation methods, for example as described in Example 1. In formula LI, M as an alkali metal is for example sodium.
Working up the reaction mixtures obtained according to the above process and purification of the compounds thus obtained may be carried out in accordance to known procedures.
Acid addition salts may be produced from the free bases in known manner, and vice versa. Suitable acid addition salts for use in accordance with the present invention include for example the hydrochloride.
The starting compounds of formula II may be produced from the corresponding compounds of formula IV
Figure imgf000006_0001
wherein X, Y, R,, R3 and R4 are as defined above, for example as described in Example 1.
The compounds of formulae III and IV are known or may be produced in analogous manner to known procedures. See for example European Patent No. 77754.
Compounds of formula I and their pharmaceutically acceptable acid addition salts, hereinafter referred to as agents of the invention, exhibit valuable pharmacological properties when tested in vitro using SRIF receptor expressing cell cultures and in animals, and are therefore useful as pharmaceuticals.
In particular the agents of the invention bind to somatostatin receptors. More particularly they are selective antagonists at Somatostatin sst, receptors, previously called SSTR-1 receptors (see Hoyer et al., TiPS, 1995, 16; 86-88), as determined in radioligand binding and second messenger studies [see for example K. Kaupmann et al., FEBS LETTERS 1993, _3±: 53-59] where they exhibit selective affinity for sstj receptors with pIC50 values between about 7.5 and 9.5.
The agents of the invention are therefore useful for treatment in anxiety, depression, schizophrenia, neurodegenerative diseases such as dementia, for the treatment of tumors and for vascular disorders and immunological diseases, as confirmed in a range of standard tests as indicated below:
At doses of about 0.3 to 3 mg/kg p.o., the agents of the invention increase exploratory behavior of mice in the open half of the half enclosed platform, a model which is predictable for anxiolytic activity (Psychopharmacology, 1986, 89:31-37).
In the same half enclosed platform model, the agents of the invention at the above indicated doses also increase vigilance of the mice. The compounds are therefore indicated for the treatment of depression, schizophrenia and dementia, in particular of senile dementia of the Alzheimer type (SDAT).
In the intruder mouse test [Triangle, 1982, 21: 95-105; J. Clin. Psychiatry, 1994, 55:9 (suppl. B) 4-7], the agents of the invention increase social investigation and reduce defensive ambivalence in the treated intruder mouse at indicated doses of about 1 to about 10 mg/kg s.c, suggesting an antidepressant profile like carbamazepine and lithium, a neuroleptic profile like clozapine and an anxiolytic profile like diazepam. Furthermore at said doses the compounds of the invention reduce aggressive behaviour (attacks, chases, bites) in the Matched Pairs Situation test in mice [Dixon et al., J. Clin. Psychiatry 55: (9) [Suppl. B] 4-7 (1994)]. Since as mentioned above they additionally attenuate defensive behaviours in the intruder mouse test, the compounds of the invention exhibit an ethopharmacological profile which is very similar to that of carbamazepine, lithium chloride and clozapine. They are therefore indicated for the treatment of affective disorders including bipolar disorders e.g. manic-depressive psychoses, extreme psychotic states e.g. mania, schizophrenia, and excessive mood swings where behavioural stabilization is desired. In addition, the compounds are indicated in anxiety states, generalized anxiety as well as social and agorophobia, as well as those behavioural states characterized by social withdrawal e.g. negative symptoms.
The agents of the invention are also effective in the treatment of various kinds of tumors, particularly of sst, receptor bearing tumors, as indicated in proliferation tests with various different cancer cell lines and in tumor growth experiments in nude mice with hormone dependent tumors [see for example: G. Weckbecker et al., Cancer Research 1994, _4: 6334- 6337]. Thus the compounds are indicated in the treatment of, for example, cancers of the breast, the prostate, the colon, the pancreas, the brain and the lung (small cell lung cancer).
For all the above mentioned indications, the appropriate dosage will of course vary depending upon, for example, the compound employed, the host, the mode of administration and the nature and severity of the condition being treated. However, in general, satisfactory results in animals are indicated to be obtained at a daily dosage of from about 0.1 to about 10 mg/kg animal body weight. In larger mammals, for example humans, an indicated daily dosage is in the range from about 5 to about 200 mg, preferably about 10 to about 100 mg of the compound conveniently administered in divided doses up to 4 times a day or in sustained release form.
The agents of the invention may be administered in free form or in pharmaceutically acceptable salt form. Such salts may be prepared in conventional manner and exhibit the same order of activity as the free compounds.
Compounds having selective sst, antagonist activity, i.e. showing selective sst] receptor affinity in the above-mentioned binding test with pIC50 values > 7.0, have never previously been described in the art. Such compounds accordingly represent an entirely novel compound group.
Accordingly in a further aspect the present invention provides selective sst, receptor antagonists for use as pharmaceuticals, more specifically for treatment in the above¬ mentioned conditions, e.g. depression, anxiety and bipolar disorders.
The present invention furthermore provides a pharmaceutical composition comprising a selective sst, receptor antagonist, e.g. an agent of the invention in association with at least one pharmaceutically acceptable diluent or carrier. Such compositions may be formulated in conventional manner. Unit dosage forms contain, for example, from about 0.25 to about 50 mg of an agent according to the invention.
Selective sst, receptor antagonists, e.g. agents of the invention may be administered by any conventional route, for example parenterally e.g. in form of injectable solutions or sus¬ pensions, or enterally, preferably orally, e.g. in the form of tablets or capsules.
For all the above- indications the preferred compound is [3R,4aR,10aR]-l,2,3,4,4a,5,10,10a- octahydro-6-methoxy- 1 -methyl-benzo[g]quinoline-3-carboxylic acid 4-(4-nitro-phenyl)- piperazine amide, which is the compound of example 1. Said compound has high affinity for rat sst, receptors (pIC50= 9.1) and recombinant human sst, receptors (p IC50 = 7.7), without significant activity for a wide range of neurotransmitter receptors. At 1-10 mg/kg s.c, the compound clearly lowers aggressive behaviour in the above-mentioned Matched Pairs Situation test and reverses social withdrawal in the above-mentioned intruder mouse test. These effects are also observed with the standard anti-manic drugs lithium and carbamazepine at 3-30 mg/kg s.c, suggesting similar therapeutic effects in man. However, lithium and carbamazepine were found to be less potent and are known to have considerable drawbacks such as narrow therapeutic window and slow onset of action.
The preferred indications are depression, anxiety and affective disorders, including bipolar disorders, e.g. mania.
In accordance with the foregoing, the present invention also provides the use of a selective sst, receptor antagonist, e.g. an agent of the invention, as a pharmaceutical, e.g. for the treatment of depression, anxiety and bipolar disorders.
Moreover the present invention provides the use of a selective sst, receptor antagonist, e.g. an agent of the invention, for the manufacture of a medicament for the treatment of any condition mentioned above, e.g. depression, anxiety and affective disorders.
In still a further aspect the present invention provides a method for the treatment of any condition mentioned above, e.g. depression, anxiety and bipolar disorders, in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a selective sst, receptor antagonist, e.g. an agent of the invention.
The following examples illustrate the invention. The temperatures are given in degrees Celsius and are uncorrected.
Example 1: f3R. 4aR. 10aR1-1.2.3.4.4a.5.10.10a-octahvdro-6-methoxy-l-methyl- benzorglquinoline-3-carboxylic acid 4-("4-nitro-phenyl)-piperazine amide
a) A mixture of 8.681 g (30 mmol) of [3R,4aR,10aR]-l-methyl-3β-methoxycarbonyl-6- methoxy-l,2,3,4,4aα,5,10,10aβ-octahydro-benzo[g]quinoline, 36 ml of methanol, 36 ml of tetrahydrofuran and 36 ml of IM aqueous sodium hydroxide solution is vigorously stirred during 16 hours at room temperature. After cooling to 0°, the reaction mixture is filtered and the product is washed with cold 2-propanol and dried at 60° in high vacuum. The so obtained sodium salt of [3R,4aR,10aR]-l-methyl-6-methoxy-l,2,3,4,4aα,5,10,10aβ- octahydro-benzo[g]quinoline-3β-carboxylic acid has a m.p. > 230° (decomposition); [α]D,20 = -138.3° (0.5 % in dimethylformamide/water 50:50).
b) A suspension of 2.973 g (10 mmol) of the sodium salt obtained under a) in 24 ml of 38 % propane-phosphonic anhydride in dimethylformamide (30 mmol) and 10 ml of absolute pyridine is stirred during 15 minutes at room temperature. After addition of 2.07 g (10 mmol) of l-(4-nitrophenyl)-piperazine, stirring is continued for 16 hours at room temperature and 100 ml of toluene and 100 ml of 2M aqueous ammonia are added. The precipitated crystals are filtered off, washed with water and toluene, dried and recrystallised in toluene. The resulting title compound has a m.p. of 218-221°. [α]D,20 = -128.7° (0.5 % in dimethylformamide).
The compounds of formula I below are produced in analogous manner to example 1.
In the following [3R,4aR,10aR] compounds, X is O, Y is CH2, R, is methyl, R2 and R3 are as indicated (OR3 is in position 6) and R4 is H.
Figure imgf000012_0001
Figure imgf000013_0001
Figure imgf000014_0001
In the following racemates, X is O, Y is O, R, is methyl, R2 and R3 are as indicated (OR3 is in position 6) and R4 is H.
Ex. R2 R3 R5 R. R7 R8 m.p. Config.
34 2-(c) Me H 179 (1)
35 167 (2)
36 (b) 4-NO2 H 176 (1)
37 222 (2)
38 2-(c) 6-CF3 154 (1)
39 142 (2)
40 3-CF3 138 (1)
In the following [3aR,4aR,10aR] compound, X is O, Y is CH2, R, is methyl, R2 and R3 are as indicated (OR3 is in position 6) and R4 is 9-Br.
Ex. R2 R3 R5 6 R7 R8 m.p. [ ]20 D **
41 (a) Me Me 216 -98.6
In the following [3aR,4aR,10aR] compound, X is O, Y is CH2, R, is H, R2 and R3 are as indicated (OR3 is in position 6) and R4 is H. Ex. R2 R3 5 Re R7 R8 m.p. [ ]20 D ***
42 (b) Me 4-NO2 H 226 -115.5
In the following racemate, X is H,H, Y is S, R, is methyl, R2 and R3 are as indicated (OR3 is in position 6) and R4 is H.
Ex. R2 R3 R5 R« R7 R8 m.p. Config.
43 2-(c) Me H 128 (2)
In the following racemate, X is O, Y is H,H, R, is methyl, R2 and R3 are as indicated (OR3 is in position 7) and R4 is H.
Ex. R2 R3 R5 6 R7 R8 m.p. Config. (decomp.)
44 (b) Me 4-NO2 H 284 (1)
Me = methyl Et = Ethyl Pr = propyl Ph = phenyl
Bn = Benzyl Ac = acetyl
* : amoφhous ** : 0.5 % in DMF ***: 0.25% in DMF
(1) = [3RS,4aRS,10aRS] racemate
(2) = [3SR,4aRS,10aRS] racemate Example 45: r3S.4aS.10aS1.1.2.3.4.4a-5-10-10a-octahvdro-6-methoxv-l-methvl. benzorglquinoline-3-carboxylic acid 4-(4-nitro-phenvP-piperazine amide
Optical isomer of the compound of example 1, produced in analogous manner to example 1. M.p. (HCl salt) = 254°; [α]20 D (free base) = + 135.3° (0.5% in DMF).

Claims

CLAIMS:
1. A compound of formula I
Figure imgf000018_0001
wherein
X is = O or H,H
Y is -CH2-, -O-, -NH- or -S-,
R, is H or (CM)alkyl,
R2 is H, benzyl, pyrimidyl, bis(4-fluorophenyl)methyl or a group of formula
Figure imgf000018_0002
(a) (b ) (c) ( )
wherein R5 is H or (CM)alkyl and R^ R7, R8 and R, independently are H, OH, NO2, CF3> (CM)alkyl, acetyl, CONR10Rπ, COOR12 [R„ and R12 independently being H or (CM)alkyl], CN or (CM)alkylsulfonyl, R3 is H, (CM)alkyl, (CM)alkylsulfonyl, trifluoromethylsulfonyl or a group of formula
Figure imgf000019_0001
wherein n is 1 to 5 and m is 1 to 3,
in free base or acid addition salt form.
2. A compound of formula I according to claim 1, wherein X, Y and R, are as defined in claim 1, R2 is H, benzyl, pyrimidyl, bis(4-fluorophenyl)methyl, naphthyl or a group of formula (a) as defined in claim 1 or of formula (b*) or (c')
Figure imgf000019_0002
<w (C)
wherein R'6 and R'7 independently are H, OH, NO2, CF3, acetyl, COOR12 (R,2 being as defined in claim 1) or CN and R'8 is H, NO2 or CN, R3 is in position 6 and is H, (CM)alkyl, methylsulfonyl, trifluoromethylsulfonyl or a group of formula
Figure imgf000019_0003
wherein n and m are as defined in claim 1 and R4 is hydrogen, the configuration in positions 4a and 10a being R, in free base or acid addition salt form. 3. A compound of claim 1 which is [3R,4aR,10aR]-l,2,
3,4,4a,5,10,10a-octahydro-6-methoxy- l-methyl-benzo[g]quinoline-3-carboxylic acid 4-(4-nitro-phenyl)-piperazine amide, in free base or acid addition salt form.
4. A selective antagonist at somatostatin sst, receptors, for use as a pharmaceutical.
5. A process for the preparation of a compound of formula I as defined in claim 1, or a salt thereof, which includes the step of reacting a compound of formula II
Figure imgf000020_0001
wherein X, Y, R„ R3 and R4 are as defined in claim 1 and M is H or an alkali metal, with a compound of formula III
HN N-R, m
wherein R2 is as defined in claim 1, and recovering the thus obtained compound of formula I in free base or acid addition salt form.
6. A compound of anyone of claims 1 to 3, in free base or pharmaceutically acceptable acid addition salt form, for use as a pharmaceutical.
7. A compound of anyone of claims 1 to 4 in free base or pharmaceutically acceptable acid addition salt form, for use in the treatment of depression, anxiety and bipolar disorders.
8. A pharmaceutical composition comprising a compound of anyone of claims 1 to 4 in free base or pharmaceutically acceptable acid addition salt form, in association with a pharmaceutical carrier or diluent.
9. The use of a compound of anyone of claims 1 to 4 in free base or pharmaceutically acceptable acid addition salt form, as a pharmaceutical, for the treatment of depression, anxiety and bipolar disorders.
10. The use of a compound of anyone of claims 1 to 4 in free base or pharmaceutically acceptable acid addition salt form, for the manufacture of a medicament for the treatment of depression, anxiety and bipolar disorders.
11. A method for the treatment of depression, anxiety and bipolar disorders in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a compound of anyone of claims 1 to 4 in free base or pharmaceutically acceptable acid addition salt form.
PCT/EP1996/002969 1995-07-07 1996-07-05 BENZO[g]QUINOLINE DERIVATIVES WO1997003054A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
SI9630315T SI0839136T1 (en) 1995-07-07 1996-07-05 BENZO(g)QUINOLINE DERIVATIVES
SK17-98A SK1798A3 (en) 1995-07-07 1996-07-05 Benzo£g|quinoline derivatives, a method of producing the same, pharmaceutical composition containing same and their use
JP9505489A JPH11509197A (en) 1995-07-07 1996-07-05 Benzo [g] quinoline derivative
DE69612852T DE69612852T2 (en) 1995-07-07 1996-07-05 BENZO [g] CHINOLINE DERIVATIVES
BR9609326A BR9609326A (en) 1995-07-07 1996-07-05 Benzo derivatives [g] quinoline
US08/983,535 US5885988A (en) 1995-07-07 1996-07-05 Benzo g!quinoline derivatives
DK96925672T DK0839136T3 (en) 1995-07-07 1996-07-05 Benzo [g] quinoline derivatives
PL96324106A PL324106A1 (en) 1995-07-07 1996-07-05 Derivatives of benzo [g] quinoline
AU66120/96A AU703325B2 (en) 1995-07-07 1996-07-05 Benzo{g}quinoline derivatives
NZ313606A NZ313606A (en) 1995-07-07 1996-07-05 Benzo[g]quinoline derivatives and pharmaceutical compositions thereof for treating depression, anxiety and bipolar disorders
EP96925672A EP0839136B1 (en) 1995-07-07 1996-07-05 BENZO[g]QUINOLINE DERIVATIVES
IL12285496A IL122854A (en) 1995-07-07 1996-07-05 Benzo ¬g¾ quinoline derivatives their preparation and pharmaceutical compositions containing them
AT96925672T ATE201199T1 (en) 1995-07-07 1996-07-05 BENZO(G)QUINOLINE DERIVATIVES
MXPA/A/1997/010530A MXPA97010530A (en) 1995-07-07 1997-12-19 Benzo (a) quinol derivatives
NO980043A NO310070B1 (en) 1995-07-07 1998-01-05 Benzo [g] quinoline derivatives, their preparation, pharmaceuticals and preparations containing them and the use of derivatives for the manufacture of medicinal products
GR20010401198T GR3036346T3 (en) 1995-07-07 2001-08-07 BENZO[g]QUINOLINE DERIVATIVES

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9513880.6A GB9513880D0 (en) 1995-07-07 1995-07-07 Organic compounds
GB9513880.6 1995-07-07
GBGB9603988.8A GB9603988D0 (en) 1996-02-26 1996-02-26 Organic compounds
GB9603988.8 1996-02-26

Publications (1)

Publication Number Publication Date
WO1997003054A1 true WO1997003054A1 (en) 1997-01-30

Family

ID=26307342

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/002969 WO1997003054A1 (en) 1995-07-07 1996-07-05 BENZO[g]QUINOLINE DERIVATIVES

Country Status (28)

Country Link
US (1) US5885988A (en)
EP (1) EP0839136B1 (en)
JP (1) JPH11509197A (en)
KR (1) KR19990028757A (en)
CN (1) CN1193964A (en)
AR (1) AR004672A1 (en)
AT (1) ATE201199T1 (en)
AU (1) AU703325B2 (en)
BR (1) BR9609326A (en)
CA (1) CA2224436A1 (en)
CO (1) CO4750662A1 (en)
CZ (1) CZ1698A3 (en)
DE (1) DE69612852T2 (en)
DK (1) DK0839136T3 (en)
ES (1) ES2158327T3 (en)
GR (1) GR3036346T3 (en)
HU (1) HUP9802937A3 (en)
IL (1) IL122854A (en)
NO (1) NO310070B1 (en)
NZ (1) NZ313606A (en)
PE (1) PE1998A1 (en)
PL (1) PL324106A1 (en)
PT (1) PT839136E (en)
RU (1) RU2158738C2 (en)
SK (1) SK1798A3 (en)
TR (1) TR199800011T1 (en)
TW (1) TW357143B (en)
WO (1) WO1997003054A1 (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998054183A2 (en) * 1997-05-29 1998-12-03 Novartis Ag Ergoline derivatives and their use as somatostatin receptor antagonists
WO1999052875A1 (en) * 1998-04-08 1999-10-21 Takeda Chemical Industries, Ltd. Amine compounds, their production and their use as somatostatin receptor antagonists or agonists
WO2000012111A2 (en) * 1998-09-01 2000-03-09 The University Of British Columbia Selective treatment of endothelial somatostatin receptors
WO2000017163A1 (en) * 1998-09-22 2000-03-30 Yamanouchi Pharmaceutical Co., Ltd. Cyanophenyl derivatives
WO2000047571A1 (en) * 1999-02-10 2000-08-17 Novartis Ag Piperidine and piperazine derivatives as inhibitors of the abeta fibril formation
WO2003006458A1 (en) * 2001-07-09 2003-01-23 Novartis Ag Benzo [g] quinoline derivatives for treating glaucoma and myopia
US7741362B2 (en) 2003-10-06 2010-06-22 Siegfried Wurster Somatostatin receptor 1 and/or 4 selective agonists and antagonists
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
US8026360B2 (en) 2004-09-20 2011-09-27 Xenon Pharmaceuticals Inc. Substituted pyridazines as stearoyl-CoA desaturase inhibitors
US8067410B2 (en) 2008-06-27 2011-11-29 H. Lundbeck A/S Phenolic and catecholic amines and prodrugs thereof
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US8541457B2 (en) 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
WO2021065985A1 (en) 2019-09-30 2021-04-08 株式会社理研バイオ－アルツハイマー病の発症前診断と予防的治療のために Somatostatin receptor
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11110110B2 (en) 2017-11-24 2021-09-07 H. Lundbeck A/S Catecholamine prodrugs for use in the treatment of Parkinson's disease
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100594234B1 (en) 2003-12-05 2006-06-30 삼성전자주식회사 Photo mask showing improved resolution by utilizing polarization of light and method of manufacturing the same
TWI404702B (en) * 2007-08-31 2013-08-11 Lundbeck & Co As H Catecholamine derivatives and prodrugs thereof
US11912687B2 (en) 2017-05-12 2024-02-27 Board of Trustees of the Southern Illinois University 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof
JP7343170B2 (en) 2017-05-12 2023-09-12 ボード オブ トラスティーズ オブ ザ サザン イリノイ ユニバーシティ オン ビハーフ オブ サザン イリノイ ユニバーシティ エドワーズビル 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0077754A2 (en) * 1981-10-16 1983-04-27 Sandoz Ag Novel pharmaceutically active 1,2,3,4,4a,5,10,10a-octahydrobenzo(g)quinoline derivatives
GB2160200A (en) * 1984-06-12 1985-12-18 Sandoz Ltd Naphth-(2,3-b)-1,4-oxazines
GB2198129A (en) * 1986-11-21 1988-06-08 Sandoz Ltd -1-(octahydrobenzo [g] quinoline-3-carbonyl)-ureas
EP0641787A1 (en) * 1993-09-03 1995-03-08 Sandoz Ltd. 2H-naphth[2,3-b]-1,4-oxazine derivatives, their preparation and their use as serotonin 1D (5-HT10) receptor agonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0077754A2 (en) * 1981-10-16 1983-04-27 Sandoz Ag Novel pharmaceutically active 1,2,3,4,4a,5,10,10a-octahydrobenzo(g)quinoline derivatives
GB2160200A (en) * 1984-06-12 1985-12-18 Sandoz Ltd Naphth-(2,3-b)-1,4-oxazines
GB2198129A (en) * 1986-11-21 1988-06-08 Sandoz Ltd -1-(octahydrobenzo [g] quinoline-3-carbonyl)-ureas
EP0641787A1 (en) * 1993-09-03 1995-03-08 Sandoz Ltd. 2H-naphth[2,3-b]-1,4-oxazine derivatives, their preparation and their use as serotonin 1D (5-HT10) receptor agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
R. NORDMANN ET AL.: "Octahydrobenzo[g]quinolines: Potent Dopamine Agonists Which Show the Relationship between Ergolines and Apomorphine", JOURNAL OF MEDICINAL CHEMISTRY, vol. 28, no. 3, 1985, pages 367 - 75, XP000608331 *

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221870B1 (en) 1997-05-29 2001-04-24 Novartis Ag Ergoline derivatives and their use as somatostatin receptor antagonists
WO1998054183A3 (en) * 1997-05-29 1999-03-04 Novartis Ag Ergoline derivatives and their use as somatostatin receptor antagonists
WO1998054183A2 (en) * 1997-05-29 1998-12-03 Novartis Ag Ergoline derivatives and their use as somatostatin receptor antagonists
WO1999052875A1 (en) * 1998-04-08 1999-10-21 Takeda Chemical Industries, Ltd. Amine compounds, their production and their use as somatostatin receptor antagonists or agonists
US6329389B1 (en) 1998-04-08 2001-12-11 Takeda Chemical Industries, Ltd. Amine compounds, their production and use
WO2000012111A2 (en) * 1998-09-01 2000-03-09 The University Of British Columbia Selective treatment of endothelial somatostatin receptors
WO2000012111A3 (en) * 1998-09-01 2000-05-25 Univ British Columbia Selective treatment of endothelial somatostatin receptors
AU754529B2 (en) * 1998-09-22 2002-11-21 Yamanouchi Pharmaceutical Co., Ltd. Cyanophenyl derivatives
WO2000017163A1 (en) * 1998-09-22 2000-03-30 Yamanouchi Pharmaceutical Co., Ltd. Cyanophenyl derivatives
US6673799B1 (en) 1998-09-22 2004-01-06 Yamanouchi Pharmaceutical Co. Ltd. Cyanophenyl derivative
WO2000047571A1 (en) * 1999-02-10 2000-08-17 Novartis Ag Piperidine and piperazine derivatives as inhibitors of the abeta fibril formation
WO2003006458A1 (en) * 2001-07-09 2003-01-23 Novartis Ag Benzo [g] quinoline derivatives for treating glaucoma and myopia
US7105528B2 (en) 2001-07-09 2006-09-12 Novartis Ag Benzo [g] quinoline derivatives for treating glaucoma and myopia
US7741362B2 (en) 2003-10-06 2010-06-22 Siegfried Wurster Somatostatin receptor 1 and/or 4 selective agonists and antagonists
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
US8026360B2 (en) 2004-09-20 2011-09-27 Xenon Pharmaceuticals Inc. Substituted pyridazines as stearoyl-CoA desaturase inhibitors
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US8541457B2 (en) 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
US8067410B2 (en) 2008-06-27 2011-11-29 H. Lundbeck A/S Phenolic and catecholic amines and prodrugs thereof
US11707476B2 (en) 2017-11-24 2023-07-25 H. Lundbeck A/S Catecholamine prodrugs for use in the treatment of parkinson's disease
US11110110B2 (en) 2017-11-24 2021-09-07 H. Lundbeck A/S Catecholamine prodrugs for use in the treatment of Parkinson's disease
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US20220185839A1 (en) 2019-05-20 2022-06-16 H. Lundbeck A/S Process for the manufacture of (2s,3s,4s,5r,6s)-3,4,5-trihydroxy-6-(((4ar,10ar)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2h-pyran-2-carboxylic acid
US11827665B2 (en) 2019-05-20 2023-11-28 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11851456B2 (en) 2019-05-20 2023-12-26 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11858954B2 (en) 2019-05-20 2024-01-02 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11866410B2 (en) 2019-05-20 2024-01-09 H. Lundbeck A/S Process for the manufacturing of (6AR,10AR)-7-propyl-6,6A,7,8,9,10,10A,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4AR, 10AR)-1-propyl-1,2,3,4,4A,5,10,10A-octahydro-benzo[G]quinoline-6,7-diol
WO2021065985A1 (en) 2019-09-30 2021-04-08 株式会社理研バイオ－アルツハイマー病の発症前診断と予防的治療のために Somatostatin receptor

Also Published As

Publication number Publication date
CA2224436A1 (en) 1997-01-30
NO980043D0 (en) 1998-01-05
GR3036346T3 (en) 2001-11-30
TW357143B (en) 1999-05-01
BR9609326A (en) 1999-05-25
DE69612852T2 (en) 2001-10-04
EP0839136B1 (en) 2001-05-16
HUP9802937A3 (en) 2002-10-28
CO4750662A1 (en) 1999-03-31
ES2158327T3 (en) 2001-09-01
JPH11509197A (en) 1999-08-17
MX9710530A (en) 1998-03-31
HUP9802937A2 (en) 1999-10-28
IL122854A0 (en) 1998-08-16
DK0839136T3 (en) 2001-08-06
AU6612096A (en) 1997-02-10
CN1193964A (en) 1998-09-23
TR199800011T1 (en) 1998-04-21
CZ1698A3 (en) 1998-04-15
ATE201199T1 (en) 2001-06-15
NO310070B1 (en) 2001-05-14
KR19990028757A (en) 1999-04-15
DE69612852D1 (en) 2001-06-21
PL324106A1 (en) 1998-05-11
PT839136E (en) 2001-09-28
RU2158738C2 (en) 2000-11-10
AR004672A1 (en) 1999-03-10
IL122854A (en) 2000-12-06
US5885988A (en) 1999-03-23
AU703325B2 (en) 1999-03-25
EP0839136A1 (en) 1998-05-06
PE1998A1 (en) 1998-02-14
NZ313606A (en) 1999-07-29
SK1798A3 (en) 1998-06-03
NO980043L (en) 1998-01-05

Similar Documents

Publication Publication Date Title
EP0839136B1 (en) BENZO[g]QUINOLINE DERIVATIVES
US5892041A (en) Fused indolecarboxamides: dopamine receptor subtype specific ligands
US6221870B1 (en) Ergoline derivatives and their use as somatostatin receptor antagonists
EP0888332B1 (en) N-Azacycloalkyl Alkyl Dibenzothiophene Carboxamides: Dopamine Receptor Subtype Specific Ligands
US5688950A (en) Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
EP1446399B1 (en) Piperazine derivatives having sst1 antagonistic activity
WO2002081471A1 (en) Beta-carboline derivatives and its pharmaceutical use against depression and anxiety
AU2002316828A1 (en) Beta-carboline derivatives and its pharmaceutical use against depression and anxiety
IL108885A (en) Benzoxazine derivatives and pharmaceutical compositions containing them
JPH0225481A (en) 2-((4-piperadinyl)methyl)-1, 2, 3, 4-tetrahydroisoquinoline derivative and its production and adaptation thereof to treatment
US6242448B1 (en) Trisubstituted-oxazole derivatives as serotonin ligands
JPH03255080A (en) Benzene compound
CA2317515A1 (en) Oxazole derivatives as serotonin-1a receptor agonists
US5081128A (en) 2,3-dihydro-1h-isoindole derivatives and their application in therapy
MXPA97010530A (en) Benzo (a) quinol derivatives
MXPA99010898A (en) Ergoline derivatives
JPH05279336A (en) Phenoxyacetic acid derivative
CA2278746A1 (en) 4-aminoethoxyindazole derivatives
JPH02231490A (en) Isothiazoloquinoline derivative
JPH04103572A (en) 4-phenyl-2-(1-piperazinyl)pyridine derivative
MXPA99001574A (en) Fused indolecarboxamides:dopamine receptor subtype specific ligands

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96196551.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996925672

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1199701152

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 313606

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2224436

Country of ref document: CA

Ref document number: 2224436

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1997/010530

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 1997 505489

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1798

Country of ref document: SK

Ref document number: PV1998-16

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1019980700056

Country of ref document: KR

Ref document number: 1998/00011

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 08983535

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: PV1998-16

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1996925672

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019980700056

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1996925672

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1998-16

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: 1019980700056

Country of ref document: KR